Chanticleer — Sonnet BioTherapeutics Holdings — Technical Presentation (April 2023)
15 slides from Chanticleer's technical presentation, Apr 18, 2023
Slide 1: Powering a New Wave of Immune Therapeutics
POWERING A NEW WAVE OF IMMUNE THERAPEUTICS SON-1010 Clinical Update Presentation April 18, 2023
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements about Sonnet BioTherapeutics based on management's current expectations which are subject to known and unknown uncertainties and risks. Words such as “anticipated,” “initiate,” “expect,” “intend,” “plan,” “believe,” “se
Slide 3: SON-1010 Executive Summary
SON-1010 EXECUTIVE SUMMARY Next Generation Oncology Platform (F,AB) Q Confers both tumor targeting and enhanced pharmacokinetics (PK); Q Fully human protein sequence, and thus, no predicted immunogenicity » First immune activator with tumor-targeting functions on a proprietary F,,AB platform » Encou
Slide 4: Sonnet Pipeline Targets
Sonnet Pipeline Targets Multiple Points of Intervention IL-18 Tumor Antigen —— Anti e resuinonts Lymph | Tumor Mature Dendritic e Cell (antigen @ presenting) eo a Antigen ffector cells: [Pee 4. Activate other immune cells 2. Kill “target cells” Activated T-cell i, Memory cells: Immature 4. Circulate
Slide 5: Sonnet's Technology Advantage
Sonnet’s Technology Advantage STRUCTURE/FUNCTION Sonnet's Fully Human Albumin Binding (FAB) technology utilizes a single chain antibody fragment (scFv) capable of delivering ‘one or two active drug compounds = Therapeutic payloads attached via flexible linker peptides Following administration, Sonne
Slide 6: FHAB: Targeting the Tumor Microenvironment
> Mono- or bifunctional cytokine(s) linked to an albumin-binding domain 010 FAB: Targeting the Tumor Microenvironment © Tumor Blood Vessel » @ Albumin is elevated in Vessel solid tumors Endothelial 2. Cells 4 FeRn over expressed in tumors on tumor vessel endothelial lining ‘Tumor Microenvironment (T
Slide 7: SON-1010: Reduces Tumor Growth in Mice
SON- 1010: Reduces Tumor Growth in Mice IL12-F,,AB vs IL-12 in B16F10 Melanoma Tumor Volume mm? + Placebo 2857 4 1L12-FHAB (1.3119) = Molar 0.9ug of 1L-12 t IL-12 (30ng) 1500 1:30 ratio of IL-12 1000 Days Single dose when tumor was 100 mm®; 8 mice/group IL-12 (1g) and IL12- FAB (1.39) are molar equi
Slide 8: Clinical Program: SB101 & SB102 Study Designs
Clinical Program: SB101 & SB102 Study Designs $B102: SAD for » Rapid enrollment of healthy volunteers in PKIPD/FACS in 300 nglkg the SAD provides clean PK data without Healthy Volunteers ose Level 4] (e700 ngs interpretation challenges from prior n=31 a a cancer treatment effects 300-3750 ngikg 3k.
Slide 9: Safety Data from SB101
Safety Data from SB101 (unausited, as of 28Fe623) 50 nel 150 ng/kg 150 > 300 fk 150 > 300 nek 150 > 540 nek Tachycardia (Grade 1) 133) Nausea (Grade 1) 1 (33.3) Chills (Grade 1) 1(33.3) 133.3) Fatigue (Grade 1) 1(33.3) 1(33.3) Injection site pain (Grade 2) 1(33.3) 3 (100.0) Pain (Grade 1) 1333) Pyre
Slide 10: SB101 Cytokine Assay Results
SB101 Cytokine Assay Results Primary PD parameters included IFNy, IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, and TNFa, assayed using the MSD platform Increases in IFNy (showing an IL-12 effect and potential for tumor control) were dose-related, controlled, and prolonged, SON-1010 induced IFNy with both th
Slide 11: SON-1010 Interim PK Analysis after Cohort
SON-1010 Interim PK Analysis after Cohort 3 » Typical dose-related increases were seen with SON-1010, with single compartment kinetics in cancer and the potential for two compartments in healthy volunteers » The preliminary geometric mean elimination half-life (ty) was 113 hours in SB101, compared t
Slide 12: SB101 Patient Response Swimmers Plot
Cohort M1 Bt ————— conortma 32 fo © Posten a © soateny 3: state see cohort ma: 2% ‘uv a2 160 : conte esponse Conort mab #3 a3 conortma 32 a Daya since sty tart a The swimmers plot shows the status for each patient and whether they had PD or SD at study entry. If patients are clinically stable and ha
Slide 13: SON-1010 Clinical Summary
200-750 ngkglSwks {500 ngikg miL-12) » Preliminary PK modeling suggests t,, in humans is >120 hours cle! Q Compares favorably with rhIL-12 ty, of 5-12 hours =» Eee » No Dose Limiting Toxicities to date in 15 patients cl jeder » Mostly mild with very few more significant AEs im | tomes a_ AEs consist
Slide 14: SON-1010 in Combination with Atezolizumab
) Biotherapeufics SON-1010 in Combination with Atezolizumab » $B221 Study: Collaboration with Roche/Genentech: » Phase 1b/2a adaptive design study to assess the safety, tolerability, PK/PD, and POC of SON-1010 alone or in combination with atezo in patients with platinum-resistant ovarian cancer (PRO
Slide 15: SON-1010 Executive Summary
SON-1010 EXECUTIVE SUMMARY Next Generation Oncology Platform (F,AB) Q Confers both tumor targeting and enhanced pharmacokinetics (PK); Q Fully human protein sequence, and thus, no predicted immunogenicity » First immune activator with tumor-targeting functions on a proprietary F,,AB platform » Encou
Sonnet BioTherapeutics Holdings — Technical Presentation (April 2023) on 6ix